Nanobiotix Shares Drop to €44.46 After a 1,181% Annual Surge and a Record High of €45.86
French biotech Nanobiotix experiences a setback after a week of euphoria. Its shares fell by 3.72% to €44.46 during mid-session Friday, following a historic peak at €45.86 on Thursday. The stock is now among the lowest performers in the SBF 120 index, which itself declined by 1.36%.
Profit-Taking After a 24% Rally Over the Week
At €44.46, the stock still maintains a spectacular lead of nearly 24% over seven days and 1,181% over a year. Today's session marks the first real pause since the record of €45.86 reached on Thursday, as already reported in our previous brief. The biotech company from the Paris region had been setting a series of historical highs since May 11, initially driven by the FDA's approval of the amendment to the Phase 3 NANORAY-312 trial protocol on head and neck cancer. The decline occurs in a weakened Parisian environment: the CAC 40 is down 1.37% at 7,971 points, and the SBF 120 loses 1.36%. The one-month volatility is high, at 24.57%, reflecting the recent wide movements in the stock.
Price Clings to the Upper Bollinger Band, a Sign of Overheating
The technical setup illustrates a short-term exhaustion of the rally. The price is at the TOP of the Bollinger band, 98% of the upper limit set at €44.99. An RSI at 79 confirms a marked overbought zone. The stock remains well above all its moving averages: 38.1% above the MM20 (€32.19) and 130.7% above the MM200 (€19.27), a gap that measures the extent of the recent bullish detachment. The resistance at €46.18, corresponding to the previous day's peak, remains the technical ceiling reference. In sectoral stocks, Sanofi is up 0.94% while Eurofins Scientific is down 0.98%. There are no financial events scheduled in the short term for the biotech, the next market step being the digestion of the record sequence from the week.
